Colorectal cancer patients benefited when they continued to include Avastin® (bevacizumab) in their chemotherapy plan after their cancer got worse after initial treatment.
They lived longer after beginning a second round of chemotherapy with Avastin than did other patients who got chemo without Avastin or those who didn’t get any chemotherapy at all.
The results are based on the ARIES study which observed patients after cancer progressed after either first or second line chemotherapy with Avastin. The analysis will be presented at the American Society of Clinical Oncology in June. Read the rest of this entry »